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Activator of LFA-1-ICAM-1 Binding**
Martin Hintersteiner,* Jçrg Kallen, Mario Schmied, Christine Graf, Thomas Jung,
Gemma Mudd, Steven Shave, Hubert Gstach, and Manfred Auer*
Abstract: Stabilization of protein–protein interactions by
small molecules is a concept with few examples reported to
date. Herein we describe the identification and X-ray co-crystal
structure determination of IBE-667, an ICAM-1 binding
enhancer for LFA-1. IBE-667 was designed based on the
SAR information obtained from an on-bead screen of tagged
one-bead one-compound combinatorial libraries by confocal
nanoscanning and bead picking (CONA). Cellular assays
demonstrate the activity of IBE-667 in promoting the binding
of LFA-1 on activated immune cells to ICAM-1.
The integrin leucocyte function-associated antigen 1 (LFA-
1) is a heterodimeric immune receptor ubiquitously expressed
on leucocytes. Its interaction with intercellular adhesion
molecule 1 (ICAM-1) provides a critical recognition event
between T-cells and antigen presenting cells in efforts by the
immune system to pull off an early-stage cell-mediated
immune response.[1–3] The LFA-1/ICAM-1 axis has thus
been explored as a target interaction for drug discovery.[4–7]
The conformational switch between low-affinity and high-
affinity states of LFA-1 upon activation and ICAM-1 binding
provides a challenge for the design of LFA-1–ICAM-1 inter-
action inhibitors.[8, 9]
While protein–protein interaction (PPI) inhibition by
small molecules was long considered to be the ultimate art in
drug design, even fewer examples of true agonists of PPIs
have been reported.[10–13] Conceptually, however, there is
evidence for clear advantages of PPI stabilizers.[14]
LFA-1 activators would be useful for treatment of rare
hereditary genetic disorders known as leucocyte adhesion
deficiency (LAD) or as potential enhancers of tumor
immunotherapy.[15, 16] One apparent activator has been de-
scribed.[17] However, closer investigation revealed that the
compound ultimately worked as an inhibitor by binding to the
b2 MIDAS domain and by blocking leucocyte transendothe-
lial migration.
One of the features of on-bead screening as an affinity
based screening method is that the identified ligands can have
different biological activity profiles and modes of action. The
ability to confirm the primary on-bead hits by measuring their
binding to target protein in homogenous solution is essential
for an efficient use of one-bead one-compound (OBOC)
library screening.[19,20] We have previously described two
different methods of how to use tagged OBOC libraries to
link on-bead screening with solution-based assays. PS/PS
relies on including a generic tagging site for post-screening
in situ labeling of hit compounds with a fluorescent dye and
subsequent miniaturized affinity determination in solu-
tion.[21, 22] The second approach uses a chemically stable UV-
fluorophore, AIDA, as a permanent tag introduced on each
compound during library synthesis.[23,24] The indazole dye,
AIDA, is then used as mass-tag for decoding and as a tracer
for affinity determination.
In an effort to apply this AIDA technology for the
identification of LFA-1 ligands, we designed a target-biased
diazepanone library (Scheme 1). This library, comprising
a total of more than 75000 compounds, was synthesized on
90 mm TentaGel beads using standard solid-phase synthesis
methods.
Screening with fluorescently labeled LFA-1 I domain
(LFA-1 ID) as target protein according to previous proce-
dures for CONA on-bead screens yielded several inhibitors of
various potencies with mm to nm dissociation constants (Kd).
However, close analysis of MS spectra during hit-bead
decoding also revealed the presence of a precursor compound
with exact mass of 427.20, corresponding to structure 1 (Fig-
ure 1A). The local concentration or density of compounds on
the surface of TentaGel beads is very high compared to
standard screening concentrations in homogenous solutions.
Consequently, the presence of binding-competent minor
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impurities can lead to target protein binding during on-bead
screening. We therefore re-synthesized compound 1 to test its
binding activity for fluorescently tagged LFA-1 ID using the
same on-bead screening assay. Surprisingly, the resynthesized
AIDA-alkyl diamine structure 1 showed very strong target
protein binding, indicated by 100 % ring formation in the
CONA screening image (Figure 1B).
A further on-bead activity test showed that the interaction
of compound 1 with LFA-1 ID was specific as no target
protein binding was detected with the homologous MAC-1 ID
(Figure 1C). Furthermore, during SAR analysis, the presence
of the aminoalkyl moiety proved to be an essential require-
ment for binding (Figure 1C, compounds 2 versus compound
3), whereas an inversion of the second amide bond and
a shortening of the alkyl chain by one carbon atom still
resulted in target-protein binding (Figure 1C, compound 4).
To confirm the interaction found with compound 1 in
homogenous solution, we performed fluorescence titrations,
using unlabeled LFA-1 ID as receptor and AIDA-fluores-
cence emission intensity as the read-out. Upon incubation of
AIDA compound 1 with LFA-1 ID, a concentration-depen-
dent fluorescence intensity increase was detected. Curve
fitting resulted in a dissociation constant of Kd = 52 nm
(Figure 2A). However, when soluble ICAM-1 was tested for
its ability to compete with this interaction between LFA-1 ID
Scheme 1. The AIDA-tagged one-bead one-compound library screening
concept. The 1,3-diaryl-substituted indazole dye AIDA is incorporated
into the solid-phase combinatorial library synthesis as first building
block. A diaminopropane spacer separates the combinatorial library,
consisting of 1,4-diazepan-2-ones, from the dye. After incubation of
the library beads with fluorescently labeled target protein, confocal
nanoscanning (CONA)[18] is used to detect beads with bound protein.
Once hit beads have been isolated, AIDA serves as a mass-tag to
facilitate MS-decoding and as a reporter for a generic secondary
binding assay for measuring the affinity of AIDA-tagged hit com-
pounds with unlabeled target protein in homogenous solution.
Figure 1. A) Structure of compound 1 (IBE-667) identified from screen-
ing of bead-based libraries with fluorescently tagged LFA-1 ID.
B) CONA image of IBE-667 bearing beads incubated with 40 nm Cy5-
LFA-1 ID. All beads in the overview show protein binding on the
surface. One of the beads and the associated ring profile are shown
on the right. C) On-bead structure–activity relationship and specificity
testing: An amide-connected aminoalkyl group is required as substitu-
ent of the AIDA core for binding to LFA-1 ID. Fluorescently tagged
Mac-1 ID does not bind to beads bearing compounds 1, 2, 3, or 4.
Figure 2. AIDA-based fluorescence titrations of A) IBE-667 with LFA-1 I
domain and of B) IBE-667–LFA-1 ID complex with soluble ICAM-1.
A) Addition of increasing amounts of LFA-1 I domain to 23 nm IBE-667
leads to an increase of AIDA fluorescence. Non-linear curve fitting of
the experimental data produced a dissociation constant of
Kd = 523 nm. B) Incubation of the preformed LFA-1 ID–IBE-667
complex with increasing amounts of soluble ICAM-1 resulted in
a further AIDA fluorescence increase and revealed a dissociation
constant for the [LFA-1 ID–IBE-667]–soluble ICAM-1 interaction of
Kd = 762 nm.
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and compound 1, another satiable fluorescence intensity
increase was observed. For compound 1 acting as an inhibitor,
a decrease of the fluorescence intensity would be expected
owing to replacement of compound 1 from the LFA-1 ID
binding site by ICAM-1. Our data therefore suggested an
agonistic behavior of compound 1 for the interaction of LFA-
1 with ICAM-1. The fitted affinity of the LFA-1 ID/com-
pound 1 complex to ICAM-1 was 76 nm (Kd) for this
interaction (Figure 2B). For comparison, in the absence of
any activation the low affinity conformation of LFA-1 binds
ICAM-1 with an affinity of Kd = 1.5 mm.
[25]
With this in vitro characterization, we turned towards
cellular assays to confirm that compound 1 was indeed an
ICAM-1 binding enhancer for LFA-1. First, the ability of
compound 1 to increase the binding of biotinylated soluble
ICAM-1 to activated T-cells was investigated by FACS. After
isolation of PBMCs and in vitro activation of T-cells, a dose
dependent enhancement of biotinylated soluble ICAM-
1 binding was detected in presence of compound 1 after
staining with streptavidin-PE (Figure 3 A). This assay
revealed a clear enhancement of the ICAM-1 binding affinity
of LFA-1 in presence of compound 1. Also, the compound
1 induced affinity enhancement of LFA-1 for ICAM-1 was
completely reversed in presence of a known LFA-1 inhibitor
binding in the Mevinolin binding pocket of the I-domain
(Figure 3B).[6] Along with its ability to promote ICAM-
1 binding to activated T-cells, compound 1 also enhanced
aggregation of T-cells, a process which again is dependent on
LFA-1/ICAM-1 interaction (Figure 3C).[26, 27] The dose-de-
pendent induction of T-cell aggregation was completely
blocked by a monoclonal antibody directed against LFA-
1 (Figure 3D). Based on these data we dubbed our newly
identified LFA-1 agonist, ICAM-1 binding enhancer 667
(IBE-667).
To further investigate the structural basis for the inter-
action of IBE-667 with LFA-1, we performed co-crystalliza-
tion experiments. The complex LFA-1 I-domain/IBE-667
crystallized in an orthorhombic crystal form (a = 45.3 , b =
65.9 , c = 133.6 , space group I222) with one complex per
asymmetric unit. Diffraction data to a resolution of 1.8 
were collected. The crystal structure (PDB-ID code 4IXD)
revealed that IBE-667 does not bind to the MIDAS site of
LFA-1 but instead binds to the mevinolin/lovastatin-binding
pocket. The binding mode of IBE-667 consists of two
hydrogen-bonding moieties (amide groups) that are flanking
an extensive, rather planar aromatic moiety (the bis-pheny-
lated indazole of AIDA) (Figure 4A, B). Furthermore, the
aminoalkyl group, which is responsible for the ICAM-1 bind-
ing enhancement, does not contribute interactions to the
LFA-1 I-domain. The two flanking amide groups
form direct hydrogen bonds to Tyr166-OH and
Glu301-OE1, while the middle aromatic moiety
interacts with the aromatic part of Tyr257 and
the side chain of Lys287 (Figure 4B,C). In
particular, the aromatic interaction between
the indazole and Tyr257 probably determines
the binding mode in a crucial way. As the
aminoalkyl group of IBE-667 does not make
direct interactions with the LFA-1 I-domain, it is
rather flexible, as judged by the weak electron
density (Figure 4C). A possible additional
pseudo twofold related binding mode does not
fit the electron-density equally well because of
the asymmetry of the bond lengths between the
indazole and the two neighboring phenyl moi-
eties. Finally, an overlay of the complex struc-
tures of LFA-1 ID with a mevinolin derived
inhibitor, LFA-878, and IBE-667 clearly dem-
onstrates that the binding modes of these two
compounds are different (Figure 4D).
Overall, the binding mode of IBE-667 and
the fact that the aminoalkyl chain does not
interact directly with LFA-1 provides no obvious
explanation for its ICAM-1 binding enhance-
ment activity. A comparison of the LFA-1 ID
IBE-667 structure to previously described low-,
medium-, and high-affinity LFA-1 ID cystein
mutants[9] reveals that only small perturbations
exist in the a7 helix of the LFA-1 ID. However,
binding of mevinolin to LFA-ID, which occupies the same
binding pocket as IBE-667, causes similarly subtle changes as
found in the cystine mutant structures, but exhibits antagon-
tistic behavior.[28] Furthermore, similar to mevinolin, no
changes are observed within the MIDAS binding site as
a consequence of IBE-667 binding to LFA-1 ID. This suggests
that the IBE-667 induced increased affinity of LFA-1 to
ICAM-1 is attributable to dynamic kinetic effects, such as
differences in on-rates. The additional charge introduced by
Figure 3. Activity of IBE-667 in cellular assays. A) IBE-667 increases the binding of
biotinylated soluble ICAM-1 to activated T-cells as determined by staining with PE-
streptavidin and FACS analysis. B) Soluble ICAM-1 binding to LFA-1 expressing
activated T-cells cells in presence and absence of IBE-667 and LFA-1 inhibitor AAQ552.
C) IBE-667 leads to a concentration dependent induction of T-cell aggregation after
activation by anti CD3 and anti CD28 antibodies. D) IBE-667 induced T-cell aggrega-
tion can be completely reversed with an LFA-1 neutralizing antibody.
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the aminoalkyl group of IBE-667 could be a contributing
factor.
In conclusion, we describe the identification of IBE-667,
an ICAM-1 binding enhancing LFA-1 agonist by CONA on-
bead screening of a tagged one-bead one-compound library.
This compound, although a precursor of the original library
design, once more shows the flexibility of on-bead screening
for identification of biologically active ligands in a miniatur-
ized and cost effective way. Furthermore, it also demonstrates
the unique advantages of a tagged library approach, in the
sense that the crucial confirmation of the interaction of the
compound with the target protein in homogenous solution as
well as an elucidation of the molecular
mode of action is greatly facilitated by
having a generic and sensitive fluorescence
based assay. However, this result also
demonstrates that the reporter group
itself is not inert. Therefore, we have
already designed and reported a next-gen-
eration tagged library approach, whereby
the label is only introduced after the initial
on-bead screening step, so that the label
can only contribute to binding but not
constitute the crucial interaction ele-
ment.[21] Finally, we believe that the insight
gained from the LFA-1 ID IBE-667 co-
crystal structure provides a valuable start-
ing point for an optimized design of new
LFA-1 agonists. LFA-1 agonists could have
an intriguing potential for increasing the
efficacy of tumor immunotherapy. The
increase of LFA-1–ICAM-1 affinity by
agonistic small molecules could compen-
sate deficiencies in either LFA-1 expression
or activation as seen in the LAD syndrome,
a rare hereditary disease.
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